Press Releases

COVINGTON, Ky., April 10, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company presented a poster on BXQ-350 during the American Association for Cancer Research (AACR) Annual Meeting 2024 which took place April 5-10, 2024, in San Diego, CA. Poster details are included below. [...]

COVINGTON, Ky., Feb. 28, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical- stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Tariq Arshad, MD, MBA as Chief Medical Officer. Dr. Arshad is an oncologist with more than 25 years of experience and a successful track record of [...]

COVINGTON, Ky., Jan. 16, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced a Trials in Progress poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), being held January 18-20, 2024, in San Francisco, CA. Poster details are included below. Poster Details: Session [...]

Company now enrolling a Phase 1b/2 study in 1st Line mCRC and a PK/PD study in CIPN COVINGTON, Ky., January 5, 2024 /PRNewswire/ — Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will present at Biotech Showcase 2024 during the J.P. Morgan [...]

COVINGTON, Ky., Oct. 12, 2023 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum. The conference will be held virtually, from October 17-18, 2023. Scott Shively, CEO and [...]

COVINGTON, Ky., Oct. 10, 2023 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Dr. Catherine Pearce, DHSc, MBA, to the Company's Board of Directors, effective October 1, 2023. Dr. Catherine Pearce, DHSc, MBA Dr. Pearce is a seasoned [...]